Scientists from A*STAR’s Genome Institute of Singapore (GIS) will work with scientists from RIKEN and Samsung Medical Centre to develop a genetic reference for Asian populations, and deepen the understanding of the drivers of health and disease
Group photo of the AIDA team in GIS (from left): Dr Shvetha Sankaran, Dr Nirmala Arul Rayan, Dr Deepa Rajagopalan, Dr Shyam Prabhakar, Mr Honardoost Mohammad Amin. (Copyright: A*STAR’s Genome Institute of Singapore)
SINGAPORE – With the goal of supporting the science and technology that will make it possible to cure, prevent, or manage all diseases by the end of this century, a philanthropic organisation founded by Dr Priscilla Chan and Mark Zuckerberg in 2015, awarded its first Asian research network grant. It was awarded to a team of scientists from Singapore, Japan, and the Republic of Korea, for their study titled “Asian Immune Diversity Atlas (AIDA)”. The team from the Agency for Science, Technology and Research’s (A*STAR’s) Genome Institute of Singapore (GIS), RIKEN, and Samsung Medical Centre, aims to identify differences in the molecular properties of blood cells across five major Asian population groups – Chinese, Japanese, Korean, Indian, and Malay. In addition, AIDA will study differences between individuals of the same ethnicity living in different countries. The results from this work could help us understand why some populations, or some individuals within a population, are more susceptible to certain diseases, and could also pave the way for new blood-based diagnostic tests.
The Chan Zuckerberg Initiative has funded this study as part of the international Human Cell Atlas (HCA) collaboration, which brings together the best scientific minds in the world to map and characterise all cell types in a healthy human body, to better understand the drivers of health and disease. The HCA has set an ambitious goal of characterising cells from diverse populations all around the world. As the flagship project of HCA-Asia, AIDA will capture data reflecting the genetic diversity of Asian populations.
AIDA, led by Dr Shyam Prabhakar (GIS), Dr Jay Shin (RIKEN), and Prof Woong Yang Park (Samsung Medical Centre), will expand the geographical scope of the HCA by defining an atlas of Asian immune cell types and states, and characterising their variations associated with ethnicity, environment, age, sex, and body mass index. While the immune system is critical in fighting germs and cancer, it is also the culprit in autoimmune diseases, in which immune cells attack an individual’s own tissues. Thus, the data generated by AIDA will be of fundamental importance for understanding how and why people differ in their disease susceptibility and response to pathogens. The study will include development of novel algorithms that integrate data generated at multiple sites to comprehensively define the properties of each cell type in human blood.
Dr Prabhakar, Associate Director of Spatial and Single Cell Systems at GIS, said, “By comprehensively characterising blood cells from over five hundred Asians, this study will lay the foundation for developing a new kind of personalised medicine.”
Prof Patrick Tan, Executive Director of GIS, said, “This regional collaboration is in line with GIS’ vision to pursue the integration of technology, genetics and biology towards academic, economic and societal impact. It will help Singapore researchers develop new methods for diagnosing, monitoring, and eventually treating a whole range of diseases related to the immune system, including autoimmune disorders, infectious diseases, cancer, and potentially even some developmental disorders.”
For media queries and clarifications, please contact:
Officer, Office of Corporate Communications
Genome Institute of Singapore, A*STAR
Tel: +65 6808 8258
About A*STAR’s Genome Institute of Singapore (GIS)
The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.
The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.
The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.
For more information about GIS, please visit www.a-star.edu.sg/gis.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.
As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.
We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.